Sharenet Sites 
Sharenet Sites
Notification in terms of Section 122(3) of The Companies Act and Section 3.83(b) of the JSE Listings Requirements
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen" or "the Company")
NOTIFICATION IN TERMS OF SECTION 122(3) OF THE COMPANIES ACT AND
SECTION 3.83(b) OF THE JSE LISTINGS REQUIREMENTS
Shareholders are referred to the SENS announcement released by the Company on 13 March
2015 wherein it was confirmed that GlaxoSmithKline (“GSK”) had announced the completion of the
disposal of half of its 12.4% shareholding in Aspen (equivalent to 28.2 million ordinary shares).
In accordance with section 122(3)(b) of the Companies Act, No. 71 of 2008 (“the Act”) and section
3.83(b) of the JSE Listings Requirements, holders of ordinary shares in the Company are advised
that GSK has now formally provided Aspen with the required notice in terms of section 122(1)(a) of
the Act. This notice confirms that GSK has disposed of 28.2 million ordinary Aspen shares and
that, as a result, its remaining beneficial interest in Aspen now amounts to 6.2% of the total number
of shares in issue.
Aspen will file the required notice with the Takeover Regulation Panel as required in terms of
section 122(3)(a) of the Act.
Durban
20 March 2015
Sponsor
Investec Bank Limited
Date: 20/03/2015 04:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
